Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:19 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD
NCT02461134 · Actelion · PHASE2 · terminated · last registry update 2025-02-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low recruitment” | – | Registry record, Actelion |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against S1PR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-01-23Phase 3 first posted: Vanda Pharmaceuticals, Ponesimod (NCT07362017)
- 2026-01-14Also stopped (withdrawn): Yale University, Etrasimod + Placebo (NCT06521762)
- 2025-12-31Results posted on the registry: Celgene, RPC1063 (NCT02531126)
- 2025-12-02Also stopped (withdrawn): Bristol-Myers Squibb, a drug against S1PR1 (NCT06181630)
- 2025-11-12Results posted on the registry: Novartis Pharmaceuticals, Ofatumumab (NCT04353492)
- 2025-11-04Results posted on the registry: Celgene, Ozanimod (NCT03440372)
- 2025-11-04Also stopped (terminated): Celgene, Ozanimod (NCT03440372)
- 2025-10-23Phase 3 first posted: TG Therapeutics, Inc., Ublituximab + Placebo (NCT07220252)
- 2025-10-09Results posted on the registry: Celgene, Ozanimod (NCT03464097)
- 2025-10-09Also stopped (terminated): Celgene, Ozanimod (NCT03464097)
- 2025-10-01Phase 3 first posted: Viatris Innovation GmbH, Cenerimod + Placebo (NCT07201129)
- 2025-09-17Results posted on the registry: Celgene, Ozanimod (NCT03467958)
- 2025-09-17Also stopped (terminated): Celgene, Ozanimod (NCT03467958)
- 2025-08-29Results posted on the registry: Novartis Pharmaceuticals, Fingolimod 0.5mg (NCT04667949)
- 2025-08-17Also stopped (withdrawn): University Hospital, Antwerp, tolerogenic dendritic cells (tolDC) + Standard-of-care (NCT06715605)
- 2025-07-15Results posted on the registry: Pfizer, Etrasimod + Placebo (NCT04607837)
- 2025-06-12Also stopped (terminated): Celgene, RPC-1063 (NCT04140305)
- 2025-05-13Results posted on the registry: State University of New York at Buffalo, Mayzent + Ocrevus (NCT04925557)
- 2025-05-13Also stopped (terminated): State University of New York at Buffalo, Mayzent + Ocrevus (NCT04925557)
- 2025-05-08Results posted on the registry: Pfizer, etrasimod + Placebo (NCT05732454)
- 2025-05-08Also stopped (terminated): Pfizer, etrasimod + Placebo (NCT05732454)
- 2025-04-22Results posted on the registry: Bristol-Myers Squibb, Ozanimod (NCT05470985)
- 2025-04-22Also stopped (terminated): Bristol-Myers Squibb, Ozanimod (NCT05470985)
- 2025-03-26Also stopped (terminated): Bristol-Myers Squibb, Ozanimod + Placebo (NCT05644665)
- 2025-03-24Results posted on the registry: Pfizer, Etrasimod Immediate Release (IR) (NCT06140290)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision